This company is no longer active
DMK Pharmaceuticals (0A4X) Stock Overview
A clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
0A4X Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
DMK Pharmaceuticals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0009 |
| 52 Week High | US$1.03 |
| 52 Week Low | US$0.0001 |
| Beta | 1.35 |
| 1 Month Change | 0% |
| 3 Month Change | -93.02% |
| 1 Year Change | -99.82% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4X | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | -0.3% |
| 1Y | -99.8% | 11.0% | 15.8% |
Return vs Industry: 0A4X underperformed the UK Pharmaceuticals industry which returned -3.2% over the past year.
Return vs Market: 0A4X underperformed the UK Market which returned 6.3% over the past year.
Price Volatility
| 0A4X volatility | |
|---|---|
| 0A4X Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A4X's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0A4X's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | Eddie Glover | www.dmkpharmaceuticals.com |
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
DMK Pharmaceuticals Corporation Fundamentals Summary
| 0A4X fundamental statistics | |
|---|---|
| Market cap | US$10.00 |
| Earnings (TTM) | -US$21.33m |
| Revenue (TTM) | US$3.62m |
Is 0A4X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4X income statement (TTM) | |
|---|---|
| Revenue | US$3.62m |
| Cost of Revenue | US$4.97m |
| Gross Profit | -US$1.35m |
| Other Expenses | US$19.98m |
| Earnings | -US$21.33m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.11 |
| Gross Margin | -37.30% |
| Net Profit Margin | -589.28% |
| Debt/Equity Ratio | 0% |
How did 0A4X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/20 03:04 |
| End of Day Share Price | 2024/10/08 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DMK Pharmaceuticals Corporation is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Kolbert | H.C. Wainwright & Co. |
| Jason Kolbert | Maxim Group |